TARRYTOWN, N.Y., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from the Phase 3 C-POST trial, which demonstrated that...

Jan 15, 2025 · Regeneron Pharmaceuticals, Inc. announced positive results from the Phase III C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically significant and clinically meaningful improvement in the primary endpoint of disease-free survival (DFS) in patients with high-risk cutaneous ...

TARRYTOWN, N.Y., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from the Phase 3 C-POST trial, which demonstrated that...

Jan 13, 2025 · Regeneron Pharmaceuticals (REGN) announced positive results from the Phase 3 C-POST trial of Libtayo® (cemiplimab) for high-risk cutaneous squamous cell carcinoma (CSCC) post-surgery treatment. The trial demonstrated a 68% reduction in disease recurrence or death risk compared to placebo, with a median follow-up of 24 months.

May 12, 2017 · Positive Phase 3 Libtayo ® (cemiplimab) results in advanced cervical cancer presented at ESMO Virtual Plenary. Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free survival and objective response rate, compared to chemotherapy

Oct 14, 2022 · Recommendation based on a Phase 3 Libtayo trial that was first and only to demonstrate significantly improved survival compared to chemotherapy in the second-line setting irrespective of PD-L1 expression status or tumor histology.

Jan 15, 2025 · Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment for advanced NSCLC in adults with at least 50% PD-L1 expression and no EGFR, ALK or ROS1 aberrations.

Jan 13, 2025 · Regeneron Pharmaceuticals, Inc. (REGN) reported positive results from the Phase 3 C-POST trial, which showed that adjuvant treatment with PD-1 inhibitor Libtayo led to a statistically significant and clinically meaningful improvement in the primary endpoint of disease-free survival in patients with high-risk cutaneous squamous cell carcinoma aft...

May 12, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the presentation of positive results from the Phase 3 trial investigating the PD-1 inhibitor Libtayo® (cemiplimab) in...

Jan 13, 2025 · --Regeneron Pharmaceuticals, Inc. today announced positive results from the Phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo ® led to a...